ESR1 and breast carcinoma: Estrogen receptor (ER)-positive invasive type of breast cancer is common in postmenopausal women and these patients are therefore likely to obtain potential benefit from adjuvant endocrine therapy applied through tamoxifen or aromatase inhibitors (AIs) Third-generation AIs include exemestane, letrozole, and anastrozole [1, 2].